OTCMKTS:ALSE Alseres Pharmaceuticals (ALSE) Stock Price, News & Analysis → His win rate puts Warren Buffett to shame… (From Investing Daily) (Ad) Free ALSE Stock Alerts $0.0050 0.00 (0.00%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$0.0050▼$0.005050-Day Range$0.0050▼$0.005052-Week Range$0.0050▼$0.0050VolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartStock AnalysisChart Get Alseres Pharmaceuticals alerts: Email Address Ad Investing DailyHis win rate puts Warren Buffett to shame… Not long ago I joined Phil Ash for a private one-on-one interview. And during our time together I pulled the covers of my investing system that’s delivered 779 winners and 43,509% total profits since November of 2015… Without a single loss.Click here now for the full story. About Alseres Pharmaceuticals Stock (OTCMKTS:ALSE)Alseres Pharmaceuticals, Inc. focuses on developing diagnostic and therapeutic products primarily for disorders in the central nervous system. Its lead product candidate is Altropane, a molecular imaging agent for the diagnosis of Parkinson's disease and dementia. The company was formerly known as Boston Life Sciences, Inc. and changed its name to Alseres Pharmaceuticals, Inc. in June 2007. Alseres Pharmaceuticals, Inc. was founded in 1972 and is based in Auburndale, Massachusetts.Read More ALSE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ALSE Stock News HeadlinesAugust 12, 2023 | uk.investing.comFTSE 350 Pharmaceuticals & Biotechnology (FTNMX201030)April 29, 2023 | marketwatch.comContrast Media Contrast Agents Market Overview and Scope By 2031April 28, 2024 | Investing Daily (Ad)His win rate puts Warren Buffett to shame… Not long ago I joined Phil Ash for a private one-on-one interview. And during our time together I pulled the covers of my investing system that’s delivered 779 winners and 43,509% total profits since November of 2015… Without a single loss.April 12, 2023 | marketwatch.comContrast Agents Market Growth by 2031March 27, 2023 | marketwatch.comContrast Media Contrast Agents Market Application, Product, Sales and Forecast 2023-2029March 21, 2023 | marketwatch.com2023-2028 Contrast Media & Contrast Agents Market Predictions and Growth Opportunities | Latest Research ReportMarch 16, 2023 | marketwatch.comFrom 2023 to 2029, Contrast Media or Contrast Agents Market Size | Industry GrowthMarch 9, 2023 | marketwatch.comContrast Media or Contrast Agents Market is Booming in Near Future 2023-2029April 28, 2024 | Investing Daily (Ad)His win rate puts Warren Buffett to shame… Not long ago I joined Phil Ash for a private one-on-one interview. And during our time together I pulled the covers of my investing system that’s delivered 779 winners and 43,509% total profits since November of 2015… Without a single loss.March 2, 2023 | marketwatch.comContrast Media or Contrast Agents Market Growing Demand and Trends 2023 to 2028February 13, 2023 | investing.comFredun Pharmaceuticals Ltd (FRED)February 12, 2023 | marketwatch.com2023, Contrast Agents Market Latest Research Report by 2027February 3, 2023 | marketwatch.comContrast Media or Contrast Agents Market Size in 2023 Industry Demand, Industry News, Business Growth, Top Key Players Update till 2029January 25, 2023 | marketwatch.comContrast Media or Contrast Agents Market is Set to Grow in forecast period 2029January 19, 2023 | marketwatch.comContrast Media or Contrast Agents Market is Taking Hike in Revenue Along With Top Key Players Profile and Forecast 2023 To 2028December 10, 2022 | marketwatch.comContrast Media or Contrast Agents Market 2022 Company Challenges, Latest Advancements, Growth Prediction, and Forecast by 2028September 17, 2022 | marketwatch.comContrast Media & Contrast Agents Market Research report forecast 2022 To 2028, Latest Industry News, Top Company Analysis, Research Methodology.August 21, 2022 | marketwatch.comContrast Media Contrast Agents Market Share, Growth Analysis with Industry Trends 2022 Emerging Technologies, Opportunity and Forecast 2022 to 2027August 19, 2022 | marketwatch.comContrast Agents Market Witness Robust Demand With A CAGR Of 4.56% For The Forecast Period 2022-2025 | 114 Report PagesJuly 20, 2022 | marketwatch.comNeurological Biomarkers Market Forecast 2022 to 2030 A Valuable Repository of Information for Key StakeholdersDecember 6, 2021 | uk.finance.yahoo.comNeurological Biomarkers Market by Application, by Type, by End-use, by Region and Forecasts to 2028December 3, 2021 | ca.finance.yahoo.comGlobal Neurological Biomarkers Market (2021-2028): Increased Funding for R&D In Biomarkers Expected to Propel Market Growth - ResearchAndMarkets.comNovember 12, 2021 | ca.finance.yahoo.comAlseres Pharmaceuticals, Inc. (ALSE)November 3, 2021 | yahoo.comNew Study from StrategyR Highlights a $8.9 Billion Global Market for Radiopharmaceuticals by 2026August 5, 2021 | finance.yahoo.comGlobal Radiopharmaceuticals Market to Reach $9.1 Billion by 2026July 28, 2021 | benzinga.comGlobal Radiopharmaceuticals Market to Reach US$9.9 Billion by the Year 2027See More Headlines Receive ALSE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alseres Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/28/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolOTCMKTS:ALSE CUSIPN/A CIKN/A Webwww.alseres.com Phone(617) 419-3289Fax508-497-9964Employees3Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable Beta0.15 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Peter G. Savas (Age 76)Executive Chairman Comp: $401.62kMr. Sam MartinDirector of Finance & Corporate ComplianceKey CompetitorsAbliva AB (publ)OTCMKTS:NEVPFAcusphereOTCMKTS:ACUSAddex TherapeuticsOTCMKTS:ADDXFAeolus PharmaceuticalsOTCMKTS:AOLSAffymaxOTCMKTS:AFFYView All Competitors ALSE Stock Analysis - Frequently Asked Questions How have ALSE shares performed in 2024? Alseres Pharmaceuticals' stock was trading at $0.0050 at the beginning of the year. Since then, ALSE shares have increased by 0.0% and is now trading at $0.0050. View the best growth stocks for 2024 here. What other stocks do shareholders of Alseres Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Alseres Pharmaceuticals investors own include Achillion Pharmaceuticals (ACHN), ACADIA Pharmaceuticals (ACAD), Arbutus Biopharma (ABUS), Abacus Property Group (ABP), Advanced BioMedical Technologies (ABMT), Abiomed (ABMD), ARCA biopharma (ABIO), Abeona Therapeutics (ABEO) and Abcam (ABCZY). How do I buy shares of Alseres Pharmaceuticals? Shares of ALSE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:ALSE) was last updated on 4/28/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyHis win rate puts Warren Buffett to shame… Investing DailyThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressJeff Bezos Just Humiliated Elon MuskInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alseres Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
